J. Ampuero and M. Romero-gomez, Pharmacogenetics of ribavirin-induced anemia in hepatitis C, Pharmacogenomics, vol.17, pp.1587-1594, 2016.

S. Beaucourt and M. Vignuzzi, Ribavirin: a drug active against many viruses with multiple effects on virus replication and propagation. Molecular basis of ribavirin resistance, Curr. Opin. Virol, vol.8, pp.10-15, 2014.

E. Beutler, K. G. Blume, J. C. Kaplan, G. W. Lohr, B. Ramot et al., International Committee for Standardization in Haematology: recommended methods for red-cell enzyme analysis, Br. J. Haematol, vol.35, pp.331-340, 1977.

S. Bodeau, J. P. Lemouel, M. Diouf, G. Duverlie, E. Nguyen-khac et al., Hemoglobin during ribavirin-based HCV therapy is closely related to circulating levels of DHEA, J. Med. Virol, vol.89, issue.6, pp.1033-1039, 2017.

E. Brochot, S. Bodeau, E. Nguyen-khac, and G. Duverlie, DHEA and progesterone have a protective effect on ribavirin-induced hemolysis, J. Hepatol, vol.60, pp.897-898, 2014.

E. Brochot, S. Castelain, G. Duverlie, D. Capron, E. Nguyen-khac et al., Ribavirin monitoring in chronic hepatitis C therapy: anaemia versus efficacy, Antivir. Ther, vol.15, pp.687-695, 2010.

E. Brochot, G. Duverlie, S. Castelain, V. Morel, C. Wychowski et al., Effect of ribavirin on the hepatitis C virus (JFH-1) and its correlation with interferon sensitivity, Antivir. Ther, vol.12, pp.805-813, 2007.

E. Brochot, C. Francois, S. Castelain, F. Helle, A. N. Van-nhien et al., A new tool to study ribavirininduced haemolysis, Antivir. Ther, vol.17, pp.1311-1317, 2012.

L. De-franceschi, G. Fattovich, F. Turrini, K. Ayi, C. Brugnara et al., Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage, Hepatology, vol.31, pp.997-1004, 2000.

J. Deutsch, Maleimide as an inhibitor in measurement of erythrocyte glucose-6-phosphate dehydrogenase activity, Clin. Chem, vol.24, pp.885-889, 1978.

C. J. Endres, A. M. Moss, B. Ke, R. Govindarajan, D. S. Choi et al., The role of the equilibrative nucleoside transporter 1 (ENT1) in transport and metabolism of ribavirin by human and wild-type or Ent1-/-mouse erythrocytes, J. Pharmacol. Exp. Ther, vol.329, pp.387-398, 2009.

J. J. Feld, I. M. Jacobson, M. S. Sulkowski, F. Poordad, F. Tatsch et al., Ribavirin revisited in the era of direct-acting antiviral therapy for hepatitis C virus infection, Liver Int, vol.37, pp.5-18, 2017.

G. Gordon, M. C. Mackow, and H. R. Levy, On the mechanism of interaction of steroids with human glucose 6-phosphate dehydrogenase, Arch. Biochem. Biophys, vol.318, pp.25-29, 1995.

J. D. Graci and C. E. Cameron, Mechanisms of action of ribavirin against distinct viruses, Rev. Med. Virol, vol.16, pp.37-48, 2006.

N. M. Hamilton, M. Dawson, E. E. Fairweather, N. S. Hamilton, J. R. Hitchin et al., Novel steroid inhibitors of glucose 6-phosphate dehydrogenase, J. Med. Chem, vol.55, pp.4431-4445, 2012.

M. Homma, H. Hosono, Y. Hasegawa, and Y. Kohda, Morphological transformation and phosphatidylserine exposure in erythrocytes treated with ribavirin, Biol. Pharm. Bull, vol.32, 2009.

Y. Inoue, M. Homma, Y. Matsuzaki, M. Shibata, T. Matsumura et al., Erythrocyte ribavirin concentration for assessing hemoglobin reduction in interferon and ribavirin combination therapy, Hepatol. Res, vol.34, pp.23-27, 2006.

Y. Jiang, Y. Zhu, Q. Mu, H. Luo, Y. Zhi et al., Oxymatrine provides protection against Coxsackievirus B3-induced myocarditis in BALB/c mice, Antivir. Res, vol.141, pp.133-139, 2017.

N. Kamar, J. Izopet, S. Tripon, M. Bismuth, S. Hillaire et al., Ribavirin for chronic hepatitis E virus infection in transplant recipients, N. Engl. J. Med, vol.370, 2014.

M. C. Kleinegris, G. H. Koek, K. Mast, E. H. Mestrom, J. L. Wolfs et al., Ribavirin-induced externalization of phosphatidylserine in erythrocytes is predominantly caused by inhibition of aminophospholipid translocase activity, Eur. J. Pharmacol, vol.693, pp.1-6, 2012.

W. M. Klump, I. Bergmann, B. C. Muller, D. Ameis, R. Kandolf et al., Efficiency and safety of an early dose adjustment of ribavirin in patients infected with hepatitis C underexposed to the drug and treated with peginterferon ribavirin, Ther. Drug Monit, vol.64, pp.684-692, 1990.

P. A. Marks and J. Banks, Inhibition of mammalian glucose-6-phosphate dehydrogenase by steroids, Proc. Natl. Acad. Sci. U. S. A, vol.46, pp.447-452, 1960.

M. Mikeladze, M. S. Hedrington, N. Joy, D. B. Tate, L. M. Younk et al., Acute effects of oral dehydroepiandrosterone on counterregulatory responses during repeated hypoglycemia in healthy humans, Diabetes, vol.65, pp.3161-3170, 2016.

B. Morsches, P. Benes, H. Holzmann, and B. Henrich, , 1981.

, Arch. Dermatol. Res, vol.270, pp.49-55

J. F. Mortola and S. S. Yen, The effects of oral dehydroepiandrosterone on endocrine-metabolic parameters in postmenopausal women, J. Clin. Endocrinol. Metab, vol.71, pp.696-704, 1990.

J. Paeshuyse, K. Dallmeier, and J. Neyts, Ribavirin for the treatment of chronic hepatitis C virus infection: a review of the proposed mechanisms of action, Curr. Opin. Virol, vol.1, pp.590-598, 2011.

T. Page and J. D. Connor, The metabolism of ribavirin in erythrocytes and nucleated cells, Int. J. Biochem, vol.22, pp.379-383, 1990.

B. A. Richardson and J. Overbaugh, Basic statistical considerations in virological experiments, J. Virol, vol.79, pp.669-676, 2005.

L. Ronzoni, A. Aghemo, M. G. Rumi, G. Prati, A. Colancecco et al., Ribavirin suppresses erythroid differentiation and proliferation in chronic hepatitis C patients, J. Viral Hepat, vol.21, pp.416-423, 2014.

T. M. Scherzer, A. F. Stattermayer, R. Stauber, A. Maieron, M. Strasser et al., Effect of gender and ITPA polymorphisms on ribavirin-induced anemia in chronic hepatitis C patients, J. Hepatol, vol.59, pp.964-971, 2013.

R. E. Schopf, F. J. Muller, P. Benes, and B. Morsches, Augmented glucose-6-phosphate dehydrogenase activity and normal penetration and metabolism of dehydroepiandrosterone in mononuclear leukocytes in psoriasis, 1986.

, Dermatol. Res, vol.278, pp.393-397

B. Testoni, D. Durantel, F. Lebosse, J. Fresquet, F. Helle et al., Ribavirin restores IFNalpha responsiveness in HCV-infected livers by epigenetic remodelling at interferon stimulated genes, Gut, vol.65, pp.672-682, 2016.

D. R. Thorburn and P. W. Kuchel, Regulation of the human-erythrocyte hexosemonophosphate shunt under conditions of oxidative stress. A study using NMR spectroscopy, a kinetic isotope effect, a reconstituted system and computer simulation, Eur. J. Biochem, vol.150, pp.371-386, 1985.

W. N. Tian, L. D. Braunstein, J. Pang, K. M. Stuhlmeier, Q. C. Xi et al., Importance of glucose-6-phosphate dehydrogenase activity for cell growth, J. Biol. Chem, vol.273, pp.10609-10617, 1998.

D. Todt, S. Walter, R. J. Brown, and E. Steinmann, Mutagenic effects of ribavirin on hepatitis E virus -viral extinction versus selection of fitness-enhancing mutations, Viruses, vol.8, p.283, 2016.

N. I. Torres, V. Castilla, A. C. Bruttomesso, J. Eiras, L. R. Galagovsky et al., In vitro antiviral activity of dehydroepiandrosterone, 17 synthetic analogs and ERK modulators against herpes simplex virus type 1. Antivir. Res. 95, 37e48, Ann. Hepatol, vol.8, pp.316-324, 2009.

S. Welle, R. Jozefowicz, and M. Statt, Failure of dehydroepiandrosterone to influence energy and protein metabolism in humans, J. Clin. Endocrinol. Metab, vol.71, 1990.

L. S. Wu, L. C. Jimmerson, C. E. Macbrayne, J. J. Kiser, and D. Z. D'argenio, Modeling ribavirin-induced anemia in patients with chronic hepatitis C virus, CPT Pharmacometrics Syst. Pharmacol, vol.5, pp.65-73, 2016.

L. Handala, Antiviral Research, vol.146, pp.153-160, 2017.